NCT02654899View on ClinicalTrials.gov

Single Dose Study of PF-06815345 in Healthy Subjects

PHASE1TerminatedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Hypercholesterolemia
Interventions
DRUG

PF-06815345

PF-06815345 will be administered as a liquid dosage formulation

OTHER

Placebo

Placebo

DRUG

PF-06815345

PF-06815345 will be administered as either solid dosage formulation or liquid dosage formulation

Trial Locations (1)

1070

Pfizer Clinical Research Unit, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02654899 - Single Dose Study of PF-06815345 in Healthy Subjects | Biotech Hunter | Biotech Hunter